{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:00:33Z","timestamp":1790168433610,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41568-026-00978-0","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:59:50Z","timestamp":1787911190000},"page":"745-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The long return on discovery science in cancer therapeutics"],"prefix":"10.1038","volume":"26","author":[{"given":"Cian","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Hume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4299-3018","authenticated-orcid":false,"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"978_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/307521a0","volume":"307","author":"J Downward","year":"1984","unstructured":"Downward, J. et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307, 521\u2013527 (1984).","journal-title":"Nature"},{"key":"978_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","volume":"22","author":"G Giaccone","year":"2004","unstructured":"Giaccone, G. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 1. J. Clin. Oncol. 22, 777\u2013784 (2004).","journal-title":"J. Clin. Oncol."},{"key":"978_CR3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129\u20132139 (2004).","journal-title":"N. Engl. J. Med."},{"key":"978_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S. et al. Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947\u2013957 (2009).","journal-title":"N. Engl. J. Med."},{"key":"978_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1056\/NEJMoa2510308","volume":"394","author":"PA J\u00e4nne","year":"2026","unstructured":"J\u00e4nne, P. A. et al. Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 394, 27\u201338 (2026).","journal-title":"N. Engl. J. Med."},{"key":"978_CR6","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","volume":"393","author":"JC-H Yang","year":"2025","unstructured":"Yang, J. C.-H. et al. Overall survival with Amivantamab\u2013Lazertinib in EGFR -Mutated Advanced NSCLC. N. Engl. J. Med. 393, 1681\u20131693 (2025).","journal-title":"N. Engl. J. Med."},{"key":"978_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/312513a0","volume":"312","author":"AL Schechter","year":"1984","unstructured":"Schechter, A. L. et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312, 513\u2013516 (1984).","journal-title":"Nature"},{"key":"978_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182 (1987).","journal-title":"Science"},{"key":"978_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783\u2013792 (2001).","journal-title":"N. Engl. J. Med."},{"key":"978_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn, R. S. et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11, R77 (2009).","journal-title":"Breast Cancer Res."},{"key":"978_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013).","journal-title":"Nature"},{"key":"978_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2605555","volume":"395","author":"EM O\u2019Reilly","year":"2026","unstructured":"O\u2019Reilly, E. M. et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N. Engl. J. Med. 395, 325\u2013337 (2026).","journal-title":"N. Engl. J. Med."},{"key":"978_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446\u2013451 (2017).","journal-title":"Nature"},{"key":"978_CR14","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261\u20132272 (2022).","journal-title":"N. Engl. J. Med."},{"key":"978_CR15","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","volume":"393","author":"T Powles","year":"2025","unstructured":"Powles, T. et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N. Engl. J. Med. 393, 2395\u20132408 (2025).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00978-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00978-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00978-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:01:56Z","timestamp":1790164916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00978-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["978"],"URL":"https:\/\/doi.org\/10.1038\/s41568-026-00978-0","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"28 August 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, the Supplementary information files were missing. These have now been made available online.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.S. acknowledges grant support from Invitae (previously Archer Dx Inc - collaboration in minimal residual disease sequencing technologies) and Personalis. He is co-chief investigator of the NHS Galleri trial funded by GRAIL and is a paid member of GRAIL\u2019s scientific advisory board. C.S. has been a paid board member for Novartis since March 2026; was\u00a0previously\u00a0a paid board member of Bicycle Therapeutics and chair of its clinical advisory group. He has received\/receives consultant or advisory fees from Genentech and China Innovation Centre of Roche (CICoR)-Shanghai; Medicxi Ventures; Relay Therapeutics (scientific advisory board member); Saga Diagnostics (scientific advisory board member); and Sarah Cannon Research Institute. He previously received consultancy, advisory fees or honoraria from AstraZeneca, Pfizer and Achilles Therapeutics. C.S. has equity and\/or stock options in Bicycle Therapeutics. Novartis, Relay Therapeutics and Saga Diagnostics. He has previously held stock and was co-founder of Achilles Therapeutics. C.S. declares a patent application for methods to detect\u00a0lung cancer (PCT\/US2017\/028013); targeting neoantigens (PCT\/EP2016\/059401); identifying patient response to immune checkpoint blockade (PCT\/EP2016\/071471); methods for lung cancer detection (US20190106751A1); identifying patients who respond to cancer treatment (PCT\/GB2018\/051912); determining HLA LOH (PCT\/GB2018\/052004); predicting survival rates of patients with cancer (PCT\/GB2020\/050221); methods and systems for tumour monitoring (PCT\/EP2022\/077987); analysis of HLA alleles transcriptional deregulation (PCT\/EP2023\/059039); technique for detecting minimal residual disease (PCT\/EP2023\/065074); relating to the use of plasma proteomics for risk prediction of lung cancer (PCT\/EP2025\/086701). C.S. is an inventor on a European patent application (PCT\/GB2017\/053289) relating to assay technology to detect tumour recurrence. This patent has been licensed to a commercial entity and under their terms of employment C.S is due a revenue share of any revenue generated from such license(s). C.M. and S.H. declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}